Atezolizumab + Bevacizumab
Treatment for Liver Cancer Due To Alcohol Use
Typical Dosage: Atezolizumab 1200mg IV Q3W + Bevacizumab 15mg/kg IV Q3W
Effectiveness
65%
Safety Score
50%
Clinical Trials
10
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
Atezolizumab 1200mg IV Q3W + Bevacizumab 15mg/kg IV Q3W
Time to Effect
Tumor response within 2-3 months
Treatment Duration
Until disease progression or unacceptable toxicity
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$357,000
Monitoring:$15,500
Side Effect Mgmt:$7,500
Total Annual:$380,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$195,000/QALY
QALYs Gained
0.6
Outcome-Based Costs
Cost per Responder
$1,266,667
Cost per Remission
$12,666,667
Comparison vs Sorafenib
Cost Difference
+$233,000/year
More expensive
QALY Difference
+0.40 QALYs
Better outcomes
Dominance
No dominance
Atezolizumab + Bevacizumab Outcomes
for Liver Cancer Due To Alcohol Use
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+30%
Remission Rate
+3%
Common Side Effects
Hypertension
+33%
Fatigue
+40%
Proteinuria
+15%
Diarrhea
+20%
Hemorrhage
+15%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov